| Aug 8 |
Assembly Biosciences GAAP EPS of -$1.98 beats by $0.25
|
| Aug 8 |
Assembly Biosciences: Q2 Earnings Snapshot
|
| Aug 8 |
Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates
|
| Jul 19 |
Investors in Assembly Biosciences (NASDAQ:ASMB) have unfortunately lost 90% over the last five years
|
| Jul 15 |
Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop
|
| Jul 9 |
Insiders Buying American Software And 2 Other Stocks
|
| Jun 18 |
Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection
|
| Jun 17 |
Assembly Biosciences closes $12.6M in equity financings
|
| Jun 17 |
Assembly Biosciences Announces $12.6 Million in Equity Financings
|
| Jun 10 |
Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366
|
